|
|
|
prIME Oncology invites you to view exciting news released from the 2010 Oncology Annual Meeting
in Chicago.
|
|
|
 |
|
9 JUNE 2010
|
| |
|
This expert interview with David Spigel, MD, from the Sarah Cannon Research Institute, Nashville, Tennessee, United States, and George Blumenschein, Jr, MD, from the M. D. Anderson Cancer Center, Houston, Texas, United States, along with a special eNewsflash and downloadable slides, discusses the topic of tailoring therapy for patients with advanced non-small cell lung cancer focusing on the following data releases:
#7609: Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial
From AACR: #LB-77 – A randomized double-blind placebo-controlled phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced NSCLC
|
| |
|
|
| |
|
View the expert interview and opinion with David Spigel, MD, and George Blumenschein, Jr, MD
and access the downloadable slides 
View eNewsflash
|
|
|
|
|
|
|
